

## Drug and Therapeutics Committee – Minutes

<b>Date / Time</b>	September 8 <sup>th</sup> 2022
<b>Venue</b>	WebEx
<b>Chair</b>	Prof A Morice, Chair, Professor of Respiratory Medicine
<b>Notes / Action Points</b>	Luke Storr – Senior Pharmacy Technician, Formulary HUTH
<b>Quorate: Yes / No</b>	Yes

<b>Attendance</b>	Prof A Morice, Chair, Professor of Respiratory Medicine
	Mr K McCorry, Medicines Optimisation Pharmacist, NECS
	Miss J Morgan, Professional Secretary, Principal Pharmacist – Formulary HUTH
	Mr Rakesh Kapur, Consultant Vascular Surgeon- HUTH
	Ms J Goode, Chief Pharmacist, HUTH
	Dr S Raise, GP Prescribing Lead, ER CCG
	Mr P O'Brien, Deputy Chief Pharmacist, HUTH
	Dr O Ogunbambi, Consultant Rheumatologist, HUTH

### Apologies

Dr H Klonin, Consultant Paediatrician, HUTH  
Prof T Sathyapalan, Consultant Endocrinologist, HUTH  
Prof M Lind, Vice Chair, Professor of Oncology, HUTH  
Luke Storr – Senior Pharmacy Technician, Formulary HUTH

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2022.09.01	<b>Apologies</b>	As Above.					
2022.09.02	<b>Declarations of Interest</b>	Prof A Morice wished to present a new product request- Gefapixant- to the committee for approval.					
2022.09.03	<b>Minutes of the previous meeting</b>	Accepted as an accurate record	no action required				
2022.09.04	<b>Action Tracker</b>	<p><b>Hydroxychloroquine in RA</b> JM to discuss with relevant business managers- August 2022- to escalate to PE&amp;CE JM has escalated and had no response back as of yet</p> <p><b>ARIA forms – Zoledronic acid</b> JM to write trust guidance in conjunction with DME pharmacy team JM to extend due date as item is still going through orthopaedic governance</p> <p><b>NICE Guidance</b> JM to meet with neurology about TA758. Dr Ming has been on leave JM to meet with him at a later date</p> <p><b>New Product Requests</b> JM to request feedback from Dr Jose about clonidine patches in 6 months Feedback has been received Dr Jose has used patches on 5 patients. Found beneficial, side effects have been reported but improved.</p> <p><b>Clinical guidelines – Biologics and small molecules for IBD</b> JM to meet with SS (with surgical team pharmacists) to work on updated guidance and discuss audit JG to ensure new pharmacy service to IMIC is set up- JG to chase up if service was set up New action: Add guidance to agenda when updated- JM has met with SS and have planned out the potential road map JG has meeting with Antonio further updates at next meeting</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Feedback received</p> <p>Ongoing</p>	<p>Await response from PE&amp;CE</p> <p>JM to meet Dr Ming</p> <p>Action Complete</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JG</p> <p>JM</p>	<p>3/22</p> <p>9/22</p> <p>3/22</p> <p>9/22</p> <p>5/22</p> <p>6/22</p> <p>9/22</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>KMC requested the completion of the Audit be on the action tracker along with bluetech for new patients</p> <p><b>NICE Guidance</b> JM to check with Dr Gordins regarding TA769- JM has received no reply- JM to chase again and contact Dr Gupta</p> <p><b>MHRA Drug Safety Update</b> April 2022 –Contact Mr Sedman about inclusion of pregabalin article in consultants newsletter. Aug 2022- nothing consultant newsletter JM to contact JM contacted Mr Sedman. Mr Sedman concerned that it shouldn't be a regular thing in the newsletter as it will lose its impact. JM to reply to Mr Sedman</p> <p><b>Any other business</b> Check dermatology still require potassium permanganate- No update from dermatology JM to chase</p> <p><b>New product requests</b> AM to write to applicants</p> <p><b>New product requests</b> LS to update formulary</p> <p><b>IV iron usage and formulary options</b> JM to update formulary- JM updated formulary</p> <p><b>NICE guidance</b> JM to e-mail Prof Sebastian re TA792 (filgotinib)- Prof Sebastian replied and would like item</p> <p><b>NICE guidance</b> JM to contact Dr Jose and Dr Ming re TA808 (fenfluramine)- JM has had replies from both, Dr Ming was going to look at TA. Dr Jose also looking at TA and would like to be able to prescribe item. JM to work out which service it would fall under</p> <p><b>NICE guidance</b></p>	<p>JM to add to action tracker</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action Complete</p> <p>Ongoing</p> <p>Ongoing</p>	<p>JM to chase</p> <p>JM to reply to Mr Sedman</p> <p>JM to check</p> <p></p> <p></p> <p>JM to hear back from Dr Ming and Dr Jose</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>AM</p> <p>LS</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p>	<p>5/22</p> <p>7/22</p> <p>7/22</p> <p>9/22</p> <p>9/22</p> <p>9/22</p> <p>9/22</p> <p>9/22</p> <p>9/22</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>JM to contact Dr Zaman and Emily Hardaker re TA803 (risankizumab for PA) to update dermatology guidance- Emily to update</p> <p><b>NICE guidance</b> JM to send dermatology psoriatic arthritis pathway to OO- JM has sent pathway to OO</p> <p><b>NICE guidance</b> JM to check TA809 to see if HUTH commissioned- HUTH not commissioned for TA809</p> <p><b>AOB</b> Add streptokinase to formulary- JM updated formulary</p>	<p>Action complete</p> <p>Action complete</p> <p>Action complete</p>		<p>JM</p> <p>JM</p> <p>JM</p>	<p>9/22</p> <p>9/22</p> <p>9/22</p>	
2022.09.05	<b>New Product Requests</b>	<p><b>New Product Requests:</b></p> <p>a) Gefapixant – Prof A Morice presented the request. At this time JG was temporally Chair of meeting. The item would be imported from Japan, not funded by the NHS and would be prescribed as a private prescription.</p> <p>b) Roxadustat (TA807) Discussions around demonstration of NICE compliance which is for discussion at APC</p> <p><b>ARIA Forms:</b> Nil this month</p>	<p>Approved</p> <p>Approved in line with NICE</p>	<p>AM to write to applicants LS to update formulary</p> <p>To add to APC agenda</p>	<p>AM/L S</p> <p>JM</p>	<p>9/22</p> <p>9/22</p>	
2022.09.06	<b>NICE guidance</b>	<p><b>Nice Guidance</b></p> <p><b>August 2022</b></p> <ul style="list-style-type: none"> <li>TA812 <a href="#">Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer</a></li> <li>TA813 <a href="#">Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors</a></li> <li>TA814 <a href="#">Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis</a></li> </ul>	<p>Not recommended</p> <p>ARIA form required</p> <p>ARIA form required for Abrocitinib</p> <p>Nothing for D&amp;T</p>	<p>JM discuss with Dr Zaman</p>	<p>JM</p>		

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<ul style="list-style-type: none"> <li>NG209 <a href="#">Tobacco: preventing uptake, promoting quitting and treating dependence</a></li> <li>TA815 <a href="#">Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs</a></li> <li>TA816 <a href="#">Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer</a></li> <li>TA817 <a href="#">Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence</a></li> <li>NG122 <a href="#">Lung cancer: diagnosis and management</a></li> <li>NG161 <a href="#">COVID-19 rapid guideline: delivery of systemic anticancer treatments</a></li> <li>NG17 <a href="#">Type 1 diabetes in adults: diagnosis and management</a></li> <li>TA818 <a href="#">Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma</a></li> <li>TA819 <a href="#">Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies</a></li> <li>TA820 <a href="#">Brolucizumab for treating diabetic macular oedema</a></li> <li>TA821 <a href="#">Avalglucosidase alfa for treating Pompe disease</a></li> </ul>	<p>On formulary for other TA's Pathway require updating</p> <p>New product- Aria form required</p> <p>ARIA form required</p> <p>Updated</p> <p>Updated</p> <p>Updated</p> <p>ARIA form required</p> <p>Previously discussed at D&amp;T</p> <p>On formulary</p> <p>Not HUTH</p>	<p>To add in line with NICE to formulary</p> <p>To add to back of formulary</p>	<p>JM</p> <p>JM</p>		
2022.09.07	<b>MHRA Drug safety update</b>	<ul style="list-style-type: none"> <li><a href="#">August 2022</a></li> </ul>	Noted				
2022.09.08	<b>Minutes of the Safe Medication Practice Committee</b>	Nil this month	Complete	No action required			

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2022.09.09	<b>Minutes from the Hull and East Riding Prescribing Committee</b>	Nil this month	Complete	No action required			
2022.09.10	<b>Regional Medicines Optimisation Committee</b>	Nil this month	Noted	No action required			
2022.09.11	<b>Clinical guidelines</b>	Nil this month	Noted	No action required			
2022.09.12	<b>Correspondence received</b>	<ul style="list-style-type: none"> <li>Andexanet</li> </ul>					
2022.09.13	<b>Chairs Approvals</b>	<ul style="list-style-type: none"> <li>Tecovirmat for monkey pox- Dr Patrick Lillie</li> <li>Lucentis- Rajnish Sekhri</li> <li>Pentazocine- Chronic cough-Prof Morice (Approved by Prof Lind)</li> </ul>	Approved  Approved	No action required			
2022.09.14	<b>Issues to escalate to PE&amp;CE</b>	<ul style="list-style-type: none"> <li>nil</li> </ul>					
2022.09.15	<b>Any Other Business</b>	<ul style="list-style-type: none"> <li>nil</li> </ul>					
2022.09.16	<b>Date and Time of Next Meeting</b>	13 <sup>th</sup> October 2022 8:15 am					